Publication: 2450

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma†
      QxMD      Google Scholar   
Citation:
Ann Oncol vol 27 (10) 1855-1860
Year:
2016
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
http://annonc.oxfordjournals.org/content/early/2016/08/06/annonc.mdw281.abstract?keytype=ref&ijkey=OgzhlPdheHfK1AI
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
6
Parents:
939  
Children:
None
Program:
OGC
Primary Committee:
Experimental
Sec. Committees:
   
Pharmas:
 
Grants:
P30 CA008748, U10CA180791, U10CA180821, U10CA180882, 5U10CA180833, U10 CA180821, U10 CA180822, U10 CA180833, U10 CA180867  
Corr. Author:
 
Authors:
                     
Networks:
CA043, COLUMBIA, LAPS-MN026, LAPS-MO011, LAPS-NY016, SANFORD   
Study
Alliance-A091102
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
soft tissue sarcoma, bone sarcoma, aurora kinase inhibitors, phase II clinical trials